tradingkey.logo

Myriad Genetics Inc

MYGN
View Detailed Chart

7.680USD

+0.280+3.78%
Close 09/18, 16:00ETQuotes delayed by 15 min
715.01MMarket Cap
LossP/E TTM

Myriad Genetics Inc

7.680

+0.280+3.78%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.78%

5 Days

0.00%

1 Month

+34.50%

6 Months

-22.42%

Year to Date

-43.98%

1 Year

-73.02%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
68 / 207
Overall Ranking
180 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 15 analysts
Hold
Current Rating
7.167
Target Price
-3.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.47% year-on-year.
Overvalued
The company’s latest PE is -1.78, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 100.80M shares, decreasing 1.80% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 9.15M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.07.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
Ticker SymbolMYGN
CompanyMyriad Genetics Inc
CEOMr. Samraat S. (Sam) Raha
Websitehttps://myriad.com/
KeyAI